Toremifene is a relatively new type of estrogen receptor blocker, which is approved in Germany exclusively for the treatment of breast cancer. It unfolds both agonistic and antagonistic effects and thus resembles other anti-estrogens such as tamoxifen or clomiphene. In the cleartext, this means that Fareston acts in certain tissues estrogen, in other reverts anti-estrogen. All you need to know about this is here:
For bodybuilders, both properties are of interest, as estrogens have not only hostile intentions. They have a positive effect, especially in the calcium and fat metabolism, i.e. estrogens store calcium in the bones and strengthen them. In addition, they can increase the good cholesterol (HDL, "High Density Lipoprotein") and lower the bad one (LDL, "Low Density Lipoprotein"), which is especially beneficial to steroid users working with active substances such as stanozolol or boldenone that can strongly negative influence the blood fat values.
However, the main reason why antiestrogens such as toremifene are used is their antagonistic effect on the mammary gland tissue, which is particularly pronounced in tamoxifen and toremifene. Toremifene occupies the estrogen receptors in the mammary glands, as a result of which estrogens in the blood circulation can no longer dock and become active there. Toremifene can thus prevent the swelling of the mammary glands and reduce or eliminate an existing gynecomastia. Toremifene has shown in scientific studies to have a lower estrogenic effect than tamoxifen, but it does not remain behind in blocking the estrogen receptors in the mammary glands. Both active substances are to be regarded as equivalent here.
Unfortunately, toremifene does not show any antagonistic effects in the adipose tissue, which is why the combination with strongly aromatizing steroids does not make sense to prevent excessive accumulation of water and fat. In build-up phases, such an approach can even be viewed as counterproductive, since anti-estrogens hinder the formation of IGF-1, and thus a reduction of fat and build-up of muscle.
The effect of toremifene on pituitary and hypothalamus is roughly equated with that of tamoxifen, with study material rarely seen on this subject. Toremifene may show a similar effect as tamoxifen in post-cycle therapy. However, until this has been proven in practice, toremifene should only be considered an effective remedy for gynecomastia.
In practice, 30 mg (equivalent to half a tablet "Fareston") of toremifene per day are taken over the entire cure length and possibly the discontinuation phase for preventive administration against gynecomastia. It is important that post-cycle therapy is continued with toremifene for 1-2 more weeks to avoid a rebound effect due to the estrogen still present in the blood and only hindered by the toremifene.
For targeted use against an existing gynecomastia, depending on the extent of the existing problem, between 30 and 60 mg per day are taken, as long as the swelling has decreased, which is normally the case within 2-3 weeks. Women usually do not use toremifene because the main benefit of this anti-estrogen is to fight a gynecomastia, which women usually do not suffer from. Toremifene is usually not used in competition and professional bodybuilding. The tablets are taken once a day.
As mentioned, there is a certain risk of rebound in the use of toremifene, so this active substance should be slowly excreted if used to combat gynecomastia. To do this, you simply halve the amount used and continue the intake for 1-2 weeks beyond the intended intake period.
The undesirable side effects are similar to those of tamoxifene, but occur much less frequently. You have to expect hot flashes, nausea, blurred vision, stomach / intestinal complaints and mood swings.